$RLFTF (related) copy by frenchman yhoobrd - Many of us

New Post Public Reply Private Reply Replies (0) Message Board
mc67
654
$RLFTF (related) copy by frenchman yhoobrd - Many of us here have been lambasting the FDA for their delay tactics- word is starting to spread:

“FDA regulators are wasting precious time in greenlighting a COVID vaccine as more than 2,000 Americans are dying each day and the pandemic continues to starve American society.

Pfizer submitted data detailing the safety and effectiveness of its vaccine on Nov. 22. But rather than immediately convening experts, the FDA scheduled a review meeting on Dec. 10, almost three weeks later. As Pfizer’s application sits on the shelf at the FDA awaiting authorization, about 27,000 Americans will have died. So what is the FDA doing for three weeks?

As a Johns Hopkins scientist who has conducted more than 100 clinical studies and reviewed thousands more from the scientific community at large, I can assure you that the agency’s review can be done within 24 to 48 hours without cutting any corners. They just need to work harder.

Contrary to popular belief, the FDA process is not hands-on—it does not interview vaccine trial patients or look under a microscope at the immune cells. It’s doing a statistical analysis and looking at data. For the vaccine trial, the data set is small and straightforward. If my research team, normally tasked with analyzing data on millions of patients, was asked to review the smaller Pfizer vaccine study of 43,000 patients, it would take about one hour.

The FDA also reviews manufacturing data from Pfizer on how they made the drug. But not only can that data be reviewed in a few hours, it should have been done months ago when it was available. While the FDA was waiting for Pfizer’s long-term vaccine results to come in, the agency should have anticipated this step and done it early.

The final step of the FDA review is to look at the outcomes of the study volunteers, including rates and severity of infection and side effects in the vaccine and placebo groups. Again, there is no plausible reason why this basic analysis cannot be done in 24 hours. The FDA and external scientists have a simple task: confirm or reject the review already conducted by the trial’s independent data safety monitoring board before FDA submission.

Let me be clear: The agency should not cut any corners in its review process, just cut out the sitting-around time. FDA insiders say the agency and its approximately 17,000 employees were dark for the four-day Thanksgiving holiday, including those working on the vaccine approval. It’s time the FDA adopts a sense of urgency. We’ve had Operation Warp Speed in developing vaccines but Operation Turtle Speed in reviewing the results...”

https://thedispatch.com/p/fda-career-staff-are-delaying-the

- some replies -

Zaran
thank you, sorry state we are in


m
@Bridge for future reference I would just have someone focus on the most efficacious of the two which is RLF-100, right? I don’t known if leronlimab is putting out numbers that are overall better than Aviptadil.


Bridge
I tweeted to Dr. Makary, responding to an earlier tweet of his. I know it’s probably useless, and after all what could he do? But I find myself sending out a tweet every few days to someone who may be able to raise these concerns. Maybe better than just watching this nightmarish delay, which makes so little sense.

Read your article re FDA vaccine delay. Same with COVID TREATMENTS like #Leronlimab and #Aviptadil
- In trials since April/May
- MOA against COVID is known
- Qualify for EUA: are SAFE and without doubt “may be” effective
- FDA is taking so long while so many die
- Can you help?


m
Dr. Marty should have focused on RLF-100 and it’s slow progress because it has a known safety profile whereas vaccines are not as well known. Pushing out RLF-100 in the 10’s of millions this December would have done more than the vaccines will. I could be wrong but would love to learn why.


Bridge
Thanks for posting. What an indictment! And that’s just the vaccines. We all knew it didn’t make sense that viable treatments like RLF-100 and leronlimab are still sitting on the shelf.

What the hell is going on? I don’t think it can be corruption like big pharma money. No half-way normal person would allow tens of thousands of deaths for money. It must be some combination of things like human complacency and stupidity. It’s hard to witness this nightmare.


crymeariver
They should focus on saving dying people instead of vaccinating healthy people.


frenchman
@BigGator There doesn’t seem to be a sense of urgency - the question is why?
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thesis Elements Expands Portfolio with Mappify Buy

Updated Category News Views 32

Mappify Acquisition: A Smooth Move for Higher Ed Picture a college student trying to juggle classes, work, and life like it's a circus act. That's not too far off from reality, and it's where Thesis America and its new acquisition, Mappify, come into play. By scooping up Mappify, Thesis aims to untangle this scheduling chaos for students across the board. From Data to...

Continue Reading
iHeartMedia Faces Investigation; Shares Plummet 60%

Updated Category News Views 5

A Sudden Pivot Leaves Shareholders Reeling Nothing like a company blindsiding its investors amid the bustling market chaos. Welcome to the iHeartMedia saga, where promises of profit have turned into a bitter pill for shareholders. On November 9, 2026, the radio giant pulled a fast one by drastically revising its full-year Adjusted EBITDA forecast down to $550...

Continue Reading
Supermetrics Debuts AI Campaign Manager for Marketers

Updated Category News Views 88

These days, digital marketing feels like trying to build a puzzle in a sandstorm. You've got all these pieces flying around, valuable insights buried somewhere in the mix, and you can't just toss 'em together however you like. Supermetrics steps into this whirlwind with their new tool, Campaign Manager, promising marketers a direct line from insight to action. Finally, a...

Continue Reading
Jumptuit's AI Patent Promises Health Alerts Innovation

Updated Category News Views 85

Jumptuit's Patent: A Game-Changer in Health Tech Alright, strap in—Jumptuit just nabbed a patent that might flip the script on how we think about environmental health risks. The U.S. Patent and Trademark Office finally gave Donald Leka and his brainchild, Jumptuit, the green light on something they're calling 'AI Systems and Methods for Environmental Exposure and Early...

Continue Reading
Biozen Slashes BP Measurement Time by 40%, No Sacrifice

Updated Category News Views 41

Biozen's Bold Leap in Blood Pressure Measurement You think blood pressure measurement, you think inconvenience—right? Not so fast. Biozen's got something up their sleeve that's shifting the game. At the latest American Heart Association's Scientific Sessions in Chicago, Biozen's bigwigs whipped out their new tech: the BP2000. This isn't just any update; it's a 40% cut...

Continue Reading
Broadridge's Dividend Move: A Steady Signal

Updated Category News Views 133

Broadridge Puts a Cherry on Top with Dividend Declaration Ah, dividends—the bread and butter for those of us who savor the small victories that come with holding onto our stocks. Broadridge Financial Solutions, Inc. (NYSE: BR) just dangled a juicy carrot in front of its shareholders with their freshly declared quarterly cash dividend of $1.09 per share. Now, I've been...

Continue Reading
Nevada Organic Phosphate Cancels Share Consolidation Plan

Updated Category News Views 42

Unexpected Turn for Nevada Organic Phosphate In an abrupt twist that surprised some investors, Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) (FSE: ZV8), the Canadian trailblazer in organic phosphate mining, called off its proposed share consolidation. Dropping the plan wasn't just a stroke of luck; it came after hearing the grumblings of shareholders concerned...

Continue Reading
2027 Bass Legends Honored: NAMM Awards Spotlight

Updated Category News Views 73

A Celebration of Low-End Legends When it comes to those deep, booming riffs that make your spine tingle, the bass guitar holds a special place in the world of music. And at the 2027 Bass Magazine Awards, this unsung hero of countless tracks is getting its due recognition. Folks, we're talking about a star-studded lineup of bass legends who’ve turned the world of music...

Continue Reading
Grandparents' Holiday Gift Picks: Expertly Tested Ideas

Updated Category News Views 43

Hunting for the Perfect Gift? Look No Further The holiday hustle and bustle inevitably sparks one of the annual dilemmas: What on earth should you buy those grandkids of yours? No need to get all twisted up this season. Enter ZestYears, the savvy go-to guide for grandparents who want to nail gift-giving without breaking a sweat or the bank. These folks, based out of...

Continue Reading
Pyxus Starts Exchange Offer for 8.50% Notes, 2027

Updated Category News Views 70

Pyxus Restructures Via Exchange Offer Pites, it's time for Pyxus International to show its hand. The global agricultural player has rolled up its sleeves, kicking off an exchange offer for its 8.50% notes maturing in 2027. With $148.3 million hanging in the balance, this move is their shot at managing debt and keeping things steady—like a farmer making sure the...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Genome Surgery Centers Pioneering Healthcare's Future

Updated Category News Views 128

Exploring the Future of Genome Surgery In a groundbreaking move, the Department of Health (DoH) has embarked on a partnership with the University of California, San Francisco (UCSF) and the Innovative Genomics Institute (IGI). This collaboration is set to explore the establishment of pioneering genome surgery centers. The exciting aspect of this announcement is its...

Continue Reading
Current Trends and Insights on Robinhood Markets' Stock

Updated Category News Views 191

Understanding the Latest Movements of Robinhood Markets Robinhood Markets Inc (NASDAQ: HOOD) has been making headlines recently, as its stock is currently experiencing fluctuations after a significant rally that saw shares increase by 17% last month, reaching new all-time highs. This surge has generated a mix of anticipation and speculation among investors regarding the...

Continue Reading
Italy's Manufacturing Sector Faces Severe Challenges in October

Updated Category News Views 108

Italy's Manufacturing Sector Stumbles in October Italian manufacturing is experiencing ongoing challenges, as evidenced by recent data. In October, manufacturing activity contracted for the seventh consecutive month, marking a troubling trend. The latest survey highlights an alarming decrease in output and new orders, as the sector grapples with persistent weaknesses. PMI...

Continue Reading
Globant Unleashes MuleSoft AI Pod for Faster Integration

Updated Category News Views 10

Unlocking the AI Puzzle: Webinar Speed Dials You ever swim through a mash-up of tech lingo that makes you feel like you're trudging through waist-high molasses? Well, Saddle up because that's exactly where Globant's new MuleSoft AI Pod is heading. Through Glob.AI, they're going all in on turning what used to take months into mere weeks—finally, right? In the business of...

Continue Reading
New Era for Drone Industry Following Presidential Executive Order

Updated Category News Views 121

Transformative Steps in the Drone Industry Recent developments in the drone sector are poised to revolutionize the industry, particularly in light of new initiatives from the U.S. government aimed at enhancing domestic drone production. The White House and the Department of Defense are streamlining regulations to bolster American capabilities in drone technology. This...

Continue Reading